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Introduction: This study characterizes tobacco cessation patterns 
and the association of cessation with survival among lung can-
cer patients at Roswell Park Cancer Institute: an NCI Designated 
Comprehensive Cancer Center.
Methods: Lung cancer patients presenting at this institution were 
screened with a standardized tobacco assessment, and those who had 
used tobacco within the past 30 days were automatically referred to a 
telephone-based cessation service. Demographic, clinical information, 
and self-reported tobacco use at last contact were obtained via electronic 
medical records and the Roswell Park Cancer Institute tumor registry 
for all lung cancer patients referred to the service between October 2010 
and October 2012. Descriptive statistics and Cox proportional hazards 
models were used to assess whether tobacco cessation and other factors 
were associated with lung cancer survival through May 2014.
Results: Calls were attempted to 313 of 388 lung cancer patients referred 
to the cessation service. Eighty percent of patients (250 of 313) were suc-
cessfully contacted and participated in at least one telephone-based cessa-
tion call; 40.8% (102 of 250) of persons contacted reported having quit at 
the last contact. After controlling for age, pack year history, sex, Eastern 
Cooperative Oncology Group performance status, time between diagno-
sis and last contact, tumor histology, and clinical stage, a statistically sig-
nificant increase in survival was associated with quitting compared with 
continued tobacco use at last contact (HR = 1.79; 95% confidence inter-
val: 1.14–2.82) with a median 9 month improvement in overall survival.
Conclusions: Tobacco cessation among lung cancer patients after 
diagnosis may increase overall survival.
Key Words: Tobacco, Smoking, Cessation, Lung cancer, Lung can-
cer survival.
(J Thorac Oncol. 2015;10: 1014–1019)
According to the 2014 Surgeon General’s Report, smoking by cancer patients and survivors causes adverse outcomes 
including increased overall mortality, increased cause-specific 
mortality, and increased risk for second primary cancers.1 
However, few studies have examined whether those who quit 
as a result of standardized tobacco use assessments with auto-
mated referral to cessation support are more likely to survive.2–5 
The majority of published literature utilizes retrospective 
chart reviews, with nonstandardized tobacco use determina-
tion, if recorded at all, to examine the association of tobacco 
use with cancer outcomes.3,6–8 Far fewer studies have evaluated 
the potential benefit of smoking cessation for improving cancer 
outcomes,1,5–7 although data strongly suggest that smoking ces-
sation may significantly improve survival for lung cancer.9
The need for standardized tobacco use assessments and 
cessation support has been recognized even though there is little 
prospective research on tobacco use and cancer survival.6,7 Since 
October 2010, Roswell Park Cancer Institute (RPCI) has operated 
a Tobacco Assessment and Cessation Service (TACS), completing 
standardized tobacco use assessments for every patient in the tho-
racic center with automatic referrals to a dedicated tobacco cessa-
tion counseling service. Patients can elect to opt out of the service 
once contacted by a cessation specialist.10 This article presents 
data on the following: (1) the lung cancer patients referred to the 
RPCI TACS; (2) quit rates of the referred patients; and (3) patient 
survival, comparing patients who stopped smoking with those 
who did not.
MATERIALS AND METHODS
RPCI Tobacco Cessation Service & Data Collection
This study was approved by the Institutional Review 
Board of RPCI. The tobacco assessment and automated 
referral methods for the RPCI TACS have been previously 
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described in detail.10 In brief, during the routine nursing 
assessment, all ambulatory patients are screened with a stan-
dardized tobacco assessment and if they report tobacco use in 
the past 30 days are automatically referred to a tobacco ces-
sation counseling service. This service is staffed by cessation 
specialists who provide behavioral counseling with linkage 
to pharmacologic support if needed.11 Cessation specialists 
contact referred patients 1 to 2 weeks after referral, with call 
priority for patients referred as current users. RPCI TACS is 
a clinically designed and supported service that offers ces-
sation support to patients, while relieving physicians of the 
burden of providing smoking cessation support while dealing 
with complex oncology issues. This service created a prospec-
tive cohort of thoracic clinic patients to serve as a base for 
this analysis exploring the association between cessation and 
survival.
The goal for the cessation counselors was to complete 
at least one successful contact attempt for as many patients 
as possible. Patients were considered not reached after five 
unsuccessful call attempts; if they were not reached, they were 
sent a letter informing them of the benefits of quitting and 
quitting tips, and inviting them to call the RPCI TACS for 
support. During successful phone calls, cessation specialists 
asked patients if they had been tobacco free for the prior 24 
hours. The cessation specialist asked patients who reported 
cessation if they had been tobacco free for the prior 7 days.
Data were abstracted from the electronic medical record 
(e.g., age, marital status, referring clinic, pack-year history, 
Eastern Cooperative Oncology Group (ECOG) performance 
status, and smoking status at referral), cessation specialist 
notes (e.g., call dates and outcomes), and the RPCI tumor reg-
istry (e.g., race, ethnicity, clinical stage, vital status, and sur-
vival time in months) between October 2010 and May 2014; 
survival duration was assessed in May 2014. Data were linked 
by patient medical record number, compiled into a main data-
set and deidentified.
Patient Population
Eligibility included patients seen in the RPCI tho-
racic center with histologically confirmed lung cancer, diag-
nosed on or after October 1, 2010, and who reported tobacco 
use within the 30 days before initial evaluation (n = 388). 
Established patients (i.e., not newly diagnosed with cancer), 
patients already treated outside of RPCI, and patients present-
ing for evaluation of biopsy results or for a second opinion 
were excluded (n = 9). Patients in hospice or end-of-life care, 
as indicated by the electronic medical record (EMR) or con-
tact with a family member, were also excluded (n = 27 of 388, 
7.0%). Only patients referred to the cessation service between 
October 2010 and October 2012 and with at least one success-
ful contact by the RPCI TACS were included in the survival 
analyses (n = 250 of 388, 64.4%).
Statistical Analysis
Some patients who had quit at initial referral were lost 
to follow-up (n = 75 of 388, 19.3%), whereas others had one 
cessation contact before being lost to follow-up (n = 137 of 
388, 35.3%). Patients were included in this analysis if they 
participated in at least one telephone call with the RPCI TACS. 
To account for the loss to follow-up and variable nature of 
quitting, the main cessation indicator was self-reported smok-
ing status at the last contact, which was obtained through May 
2014. To be considered as having quit, a patient had to indicate 
that he or she was tobacco-free for at least 24 hours at time of 
last contact.
ECOG performance status was routinely documented in 
the EMR for all patients by a combination of nursing staff, 
advanced practice providers, and physicians; and was dichot-
omized into those with a score of 0 (fully active, as if dis-
ease free) and those with a score of one or higher (restricted 
from strenuous activity or more severely limited, including 
deceased).12 To control for disease severity, ECOG status, 
along with tumor stage, were included in the final adjusted 
model. Clinical stage was included as a categorical variable 
with three categories; stages I and II combined served as the 
referent, with stages III and IV as comparison groups.
Descriptive statistics were used to examine the referral 
patterns, demographics, disease characteristics, self-reported 
quit rates at each contact, and self-reported status at the last 
contact. Frequencies and χ2 tests were used for categorical 
variables, ANOVA was used to analyze continuous variables 
and quit rates, and Kaplan–Meier with log-rank test for sur-
vival time with quit rates. Survival analysis was conducted 
using a Cox proportional hazards model. Vital status (alive or 
deceased at the end of follow-up) and survival time in months 
were the main outcome variables for the survival analysis. The 
date of diagnosis served at the date of origin for survival time. 
Variables included in the Cox proportional hazards model 
with support in the literature included age at diagnosis, pack-
years, days between diagnosis and last contact, sex, clinical 
stage, ECOG status, tumor histology (NSCLC vs. other), and 
tobacco use status at time of referral.3,13,14
RESULTS
Lung Cancer Patient Referrals to the 
Cessation Counseling Service
Between October 2010 and October 2012, 388 thoracic 
clinic referrals to RPCI TACS were lung cancer patients who 
met eligibility criteria for inclusion in these analyses with 
a diagnosis date between October 1, 2010 and October 31, 
2012 (Fig. 1). About 81% of those referred (313 of 388) had 
at least one cessation support call attempted, of which 250 of 
313 patients (79.9%) participated; only five (1.3%) actively 
refused participation. Among 58 patients who did not partici-
pate, 27 patients (7.0%) were in end of life care or reported to 
be deceased; 26 patients (6.7%) could not be reached, and five 
(1.3%) were considered inappropriate referrals as never users 
or they had quit greater than 30 days before referral. Seventy-
five of 388 patients (19.3%) were not called, but were sent an 
information pamphlet about the benefits of cessation, quit tips 
and an invitation to call the service. There were, on average, 
21.5 days between referral to the RPCI TACS and first contact.
Among the 250 patients who participated in at least one 
cessation support call, 149 patients (59.6%) had a follow-up 
call attempted, with 136 patients (91.3%) participating in at 
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least one follow-up call (Fig. 1). Due to staffing limitations, 
follow-up calls were not attempted to 101 persons (40.4%), 
who had one successful contact. No lung cancer patients 
actively refused participation at the first follow-up call. There 
were an average of 39.2 days between the initial cessation sup-
port call and the next follow-up call. Patients had the oppor-
tunity for a maximum of eight cessation support calls, with a 
median of 2 calls completed (range: 1–8; mean = 2.27).
Quit Rates among Lung Cancer Patients
Self-reported quitting status was assessed at each con-
tact; status reported at each contact was independent of that at 
prior contact. At time of referral to the RPCI TACS, 20.0% of 
patients (n = 50 of 250) self-reported having quit within the 
last 30 days (Table 1). At the initial phone contact, 71 of 250 
patients (28.7%) reported having quit, including newly quit 
patients and those who maintained their status from the time 
of referral. Among 136 patients who completed at least one 
follow-up call, 56 patients (41.8%) self-reported having quit. 
In total, 102 patients (40.8%) reported at least 24 hours absti-
nence at last contact, including 65 patients (63.7%), who had 
quit before the initial contact.
In bivariate analyses (not shown), patients who had quit 
at last contact, as compared with current users, had more favor-
able performance status (47.1% ECOG 0 vs. 33.0% ECOG ≥1 
had quit; p = 0.024) and were more likely to be alive (48% alive 
vs. 33.6% deceased had quit; p = 0.021). Patients who reported 
having quit at last contact had a higher mean survival time as 
compared with patients who reported continued tobacco use 
(25.2 vs. 20.0 months, p = 0.004; results not shown).
Lung Cancer Patient Survival Outcomes 
in Relation to Quit Status
There was an average of 15.5 months (median: 15.0 
months; range: 0–40 months) follow-up for survival time 
through May 2014. As of May 2014, 51.3% of the lung cancer 
population included in the final adjusted model were deceased 
(n = 115 of 224, Table 2). Older age, advanced stage, and cur-
rent tobacco use at last contact were associated with a higher 
risk of mortality with control for age at diagnosis, pack-years, 
days between diagnosis and last contact, sex, tobacco use at 
referral, ECOG status, and tumor histology (Table 2). Current 
tobacco use at the last contact was associated with a significant 
increase in death compared with patients who self-reported 
being quit (hazard ratio [HR] = 1.79, 95% confidence interval 
[CI]: 1.14–2.82). This survival advantage for quitters, after 
adjusting for the demographic, disease and health characteris-
tics previously mentioned, is depicted graphically in Figure 2. 
The median survival for patients who reported current tobacco 
use at last contact was 20 months versus 29 months for those 
who reported being quit at last contact (Fig. 2).
Adjustment for the number of completed calls did 
not affect the results; the HR for current tobacco use at last 
contact remained the same (HR = 1.78; 95% CI: 1.13–2.81; 
results not shown). Restricting the analysis to patients who 
participated in at least two calls yielded similar results 
(n = 126; HR = 2.19; 95% CI: 1.14–4.21; results not shown). 
Also, restricting to NSCLC patients who participated in one 
call, results remained similar (n = 197; HR = 2.01; 95% CI: 
1.24–3.26; results not shown). There were only 27 patients 
with other lung cancer types; the HR for continuing to use 
tobacco was similar, but not statistically significant (n = 27; 
HR = 1.99; 95% CI: 0.30–12.99; results not shown).
DISCUSSION
Lung cancer patients who quit using tobacco had sig-
nificantly better overall survival than patients who continued 
to use tobacco after diagnosis. This result persisted even with 
control for age at diagnosis, pack-year history, days between 
diagnosis and last contact, sex, clinical stage, performance 
status, tumor histology, and having quit at referral. This study 
provides evidence that lung cancer patients are interested in 
quitting tobacco. Although not a randomized trial, it provides 
limited, indirect evidence that quitting may improve survival.
The 2014 Surgeon General’s Report concluded that the 
adverse effects of smoking on cancer patients are no longer in 
question and that the effects extend across virtually all cancer 
disease sites and for all treatment modalities.1 As a result, it 
is timely to explore methods for improving outcomes among 
cancer patients by targeting smoking cessation among those 
patients; one important component could be the provision of 
cessation support.6,5 To the best of our knowledge, this is one 
of the first studies to examine the association of tobacco cessa-
tion with survival among lung cancer patients who participated 
in a systematic tobacco use program combining automated 
referral with tobacco cessation services. Using a retrospec-
tive design, Warren et al.3 found that quitting smoking dur-
ing the year before a cancer diagnosis was associated with 
improved survival among lung cancer patients compared with 
FIGURE 1.  Lung cancer patients referred to RPCI TACS from 
the thoracic center between October 2010 and October 
2012. Among the 1258 thoracic clinic patients assessed, 
which included patients of all conditions (high risk screen-
ing, survivors, second options, late stage, etc.), the tumor 
registry confirmed 556 had lung cancer, including 388 who 
met inclusion criteria with a diagnosis date after October 1, 
2010. 149 of 250 patients (59.6%), who participated in the 
first contact were called for a follow-up. 136 of 149 patients 
(91.3%) with follow-up call attempts were successfully con-
tacted again and participated; eight persons were not able 
to be reached and five were end of life or deceased, but no 
patients actively refused a follow-up call. There were an aver-
age of 21.5 days between referral to the cessation service and 
initial contact; and an average of 39.2 days between the ini-
tial call and the next follow-up call. RPCI TACS, Roswell Park 
Cancer Institute Tobacco Assessment and Cessation Service.
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patients that continued to use tobacco. Among lung cancer 
patients treated between 1982 and 1998, current smokers had 
increased mortality compared with patients quitting within a 
year of their diagnosis (HR = 1.38; 95% CI: 1.06–1.79) and 
compared with former smokers (HR = 1.43; 95% CI: 1.13–
1.81). Both this study and previous studies provide evidence 
that continued smoking after a lung cancer diagnosis appears 
to reduce survival, suggesting the importance of providing 
cessation support.3,11,15
The majority of published studies reporting on the asso-
ciation of smoking with cancer outcomes depend upon retro-
spectively collected tobacco use status, using notes in medical 
records; these can contain very limited smoking informa-
tion.3,6,5,16 Before the more recent reliance on electronic 
records and implementation of “meaningful use,” tobacco use 
was rarely collected in a standardized, prospective manner to 
support clinical outcomes research among cancer patients.3 
A strength of this study was the collection of tobacco use 
information at diagnosis and during follow-up contacts. An 
additional strength of this study is the potential reduction in 
self-selection bias for participation in the tobacco cessation 
service through the use of an opt-out requirement. Only 1.3% 
of smokers contacted by phone actively refused participa-
tion in the initial call with a similar low rate of refusal (~5%) 
for follow-up calls. Our findings suggest that standardized 
tobacco use assessments and automatic referrals to cessation 
counselors assure universal access to cessation support ser-
vices without reliance on actual clinician referrals.
In considering our results, several limitations must be 
noted. First is that, although this study was prospective, it 
was not a clinical trial. There is no control group; this study 
TABLE 1.  Self-Reported Tobacco Use Status among Lung 
Cancer Patients Referred to a Counseling Service between 
October 2010 and October 2012 and Contacted at Least 
One Time
Self-Reported  
Tobacco Use
Baseline  
(N = 250)
Initial Contact 
(N = 250)
2nd Contact 
(N = 136)
Last Contact 
(N = 250)
N (%) N (%) N (%) N (%)
Current user 200 (80.0) 176 (71.3) 78 (58.2) 148 (59.2)
Quit 50 (20.0) 71 (28.7) 56 (41.8) 102a (40.8)
The quit rates are reported independently at each contact and based on self-reported 
24 hour abstinence before contact. Baseline represents initial assessment at time of 
referral to the cessation service.
a“quit” at “last contact” includes all patients who self-reported being quit at the 
most recent contact, including patients who quit in the 30 days prior to diagnosis and 
maintained their quit status.
TABLE 2.  Adjusted Hazard Ratios for Death among Lung Cancer Patients Contacted at Least One Time between October 2010 
and October 2012 (n = 224*)
Continuous Variables N Mean Hazard Ratio 95% CI p
Age at diagnosis (years) 224 61.9 1.04 1.02–1.06 0.001
Pack-years 224 59.7 1.00 0.99–1.01 0.495
Days between diagnosis and last contact 224 100.9 0.999 0.998–1.001 0.227
Categorical Variables N % Hazard Ratio 95% CI p
Sex
  Female 134 59.8 1.00 Ref. 
1.01–2.14
0.051
  Male 90 40.2 1.45
Clinical stage
  Stage I/II 81 36.2 1.00 Ref.
1.39–4.61
4.93–15.40
<0.001†
  Stage III 65 29.0 2.53
  Stage IV 78 34.8 8.72
ECOG status
  0 127 56.7 1.00 Ref. 
0.84–1.89
0.265
  ≥1 97 43.3 1.26
Tumor histology
  NSCLC 197 87.9 1.00 Ref. 
0.50–1.52
0.626
  Other lung cancer 27 12.1 0.87
Quit status at referral
  Quit 48 21.4 1.00 Ref. 
0.48–1.34
0.393
  Current 176 78.6 0.80
Quit status at last contact
  Quit 95 42.4 1.00 Ref. 
1.14–2.82
0.012†
  Current 129 57.6 1.79
115 of 224 patients (51.3%) were deceased by the end of the follow-up period. The model is adjusted for all variables shown in this table based upon a Cox proportional hazards model.
*N = 224 of 250 due to 22 records missing clinical stage, two missing pack-years, and two missing both clinical stage and pack-years.
Bold indicates statistically significant at p < 0.05.
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; NSCLC, non–small-cell lung cancer.
Copyright © 2015 by the International Association for the Study of Lung Cancer
1018 Copyright © 2015 by the International Association for the Study of Lung Cancer
Amato et al. Journal of Thoracic Oncology ®  •  Volume 10, Number 7, July 2015
utilized a cohort generated from a standard-of-care program 
established to reach all patients. The goal of this study was 
less to document that the tobacco cessation service improved 
patient survival than to utilize a natural experiment: a prospec-
tive cohort of lung cancer patients who participated in this 
clinical service, to explore the relation between cessation and 
survival.
There is a potential for survival bias, given that patients 
who survived longer have more opportunities to quit and to 
relapse. We explored this by examining the length of time 
(in days) between diagnosis and the last contact; no signifi-
cant associations with having quit were noted. In each model 
studied, even controlling for disease severity and time since 
diagnosis, having quit at last contact was a significant pre-
dictor of subsequent survival, again suggesting that quitting 
after diagnosis may improve survival for lung cancer patients. 
Guarantee time bias resulting in spurious significant findings 
is limited in this analysis; the study is restricted to patients who 
participated in at least one telephone call, therefore remov-
ing patients who were not called or did not participate in the 
service and could not have their tobacco use status assessed. 
Inclusion of a time-dependent variable for having quit at last 
contact suggested that there is no interaction between time 
and the quit status variable that the Cox proportional hazards 
assumption was upheld, and is therefore an appropriate model 
(HR
interaction
 = 0.978; 95% CI: 0.949–1.008).
Having tobacco use status based upon self-report and 
the imperfect accuracy of patient self-report is a study limita-
tion.17 Adding biochemical confirmation of tobacco use status 
among patients participating in the cessation service is a goal 
for future studies.
Another limitation of this study is the limited sample 
size and loss to follow-up. At the beginning of the service 
priority was placed on making at least one telephone call to 
each new patient referred from the thoracic clinic as a current 
user, which reduced the number of patients with follow-up 
calls. Patients were contacted for a follow-up call only after 
attempts to contact new referrals were completed in a week. 
The goal of this approach was to provide at least some cessa-
tion support to as many patients as possible. Calling patients 
for the first and follow-up contacts was done randomly, as 
supported by the lack of statistically significant differences in 
patient demographic and disease characteristics. Current users 
at referral were significantly more likely than former users to 
be called for a first contact. The service was designed with 
current users as first priority; as a result, 83.3% of current 
users, but only 71.9% former users were called for the first 
contact (p = 0.017).
Similarly, the limited follow-up data for patients beyond 
the first call also limited the tobacco use status information 
available after the first call. Patients with only one contact 
by the cessation service may have quit afterwards, but this 
information is not available. This limitation represents one 
of the challenges associated with longitudinal study design. 
We explored multiple ways of representing having quit while 
exploring this issue, and quitters consistently survived signifi-
cantly longer than current users. Adding the number of suc-
cessful counseling support calls in the model did not change 
the results. Similarly, restricting the final model to patients 
who participated in at least two calls led to similar results 
(n = 126; HR = 2.19; 95% CI: 1.14–4.21).
Additional research, including data derived from larger 
cohorts and from cessation trials, is needed to justify the pro-
vision of tobacco cessation services as part of comprehensive 
care for cancer patients. As we accrue data for additional 
patients and extend follow-up, we plan to explore other out-
comes including disease-free survival and quality of life, and 
to extend these analyses to other cancer sites.
CONCLUSIONS
These results are unique in demonstrating that lung can-
cer patients who reported quitting smoking at or following 
their diagnosis had significantly better survival than that of 
patients who continued to use tobacco after diagnosis. This 
FIGURE 2.  Adjusted survival curve for lung 
cancer patients referred to the cessation service 
and contacted at least once between October 
2010 and October 2012, by tobacco use status 
at last contact (n = 224; n = 224 of 250 due to 
22 records missing clinical stage, two missing 
pack-years and two missing both clinical stage 
and pack-years). Follow-up ranges from 0 to 40 
months, with an average of 15.5 months; 115 
of 224 patients were deceased by the end of the 
follow-up period. The date of origin for survival 
time was the individual’s lung cancer diagnosis 
date. Lines converge at 40 months due to one 
person having the maximum of 40 months 
follow-up, who was deceased at that time and 
was a current user at the last contact. Median 
survival for current users at last contact was 
20.00 months and 29.00 months for those who 
were quit at last contact.
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represents a possibly important message for both clinicians 
and patients regarding the importance of smoking cessation.
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